Adult Soft Tissue Localized

Sarcomas
Adult Soft Tissue Localized
- Rhabdomyosarcoma
  - < 40yo and 2-5th line
  - VICCPED24617
    Donor NK Cell Infusions as Adopt Immunother Comb w/Gem & Docetax in Pts w/R/R Ped Bone & Soft Tissue
- Neoadjuvant High Risk
  - LPS/LMS/UPS Only
    - ECOGSAREA7211
      Neoadjuvant Chemo Followed by Surgery vs Surgery Alone for High-Risk Retroperitoneal Sarcoma
      - 1. Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of
        retroperitoneal space or infra-peritoneal spaces of pelvis.
        LMS _ any grade and size > 5 cm
        DDLPS; MDM2 and CDK4 expression on IHC; additional proof of MDM2 amplification is highly recommended but not mandatory
        Grade 3
        Grade 2 with:
        - FNCLCC score = 5 and clear
        necrosis on imaging (whether or not
        present on the biopsy).
        - OR CINSARC-high (high risk
        gene profile as determined by the
        Complexity INdex in SARComas)
        2. Unifocal tumour
        3. Resectable tumour: based on pre-op imaging (CT-abdomen, potentially
        also with MRI) and has to be defined by the local treating sarcoma team. Not
        considered operable when the expectation is that only an R2 resection is feasible.
        4. radiologically measurable disease
        Exclusion:
        1.Sarcoma originating from bone structure, abdominal or gynecological viscera
        2. Metastatic disease
        3. CHF, Angina pectoris, Acute infalmmatory heart disease, MI within 1 yr, Uncontrolled hypertenson, uncontrolled cardiac arrhythmia
        4. Previous treatment with max cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones
  - RetroPeritoneal Sarcoma
    - ECOGSAREA7211
      Neoadjuvant Chemo Followed by Surgery vs Surgery Alone for High-Risk Retroperitoneal Sarcoma
      - 1. Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of
        retroperitoneal space or infra-peritoneal spaces of pelvis.
        LMS _ any grade and size > 5 cm
        DDLPS; MDM2 and CDK4 expression on IHC; additional proof of MDM2 amplification is highly recommended but not mandatory
        Grade 3
        Grade 2 with:
        - FNCLCC score = 5 and clear
        necrosis on imaging (whether or not
        present on the biopsy).
        - OR CINSARC-high (high risk
        gene profile as determined by the
        Complexity INdex in SARComas)
        2. Unifocal tumour
        3. Resectable tumour: based on pre-op imaging (CT-abdomen, potentially
        also with MRI) and has to be defined by the local treating sarcoma team. Not
        considered operable when the expectation is that only an R2 resection is feasible.
        4. radiologically measurable disease
        Exclusion:
        1.Sarcoma originating from bone structure, abdominal or gynecological viscera
        2. Metastatic disease
        3. CHF, Angina pectoris, Acute infalmmatory heart disease, MI within 1 yr, Uncontrolled hypertenson, uncontrolled cardiac arrhythmia
        4. Previous treatment with max cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones
  - VICCSAR2062
    Neoadjuvant Hypofractionated XRT in STS
    - Key Eligibility:
      1. Soft tissue sarcoma of extremity, pelvis, chest wall or trunk/abdominal wall (non-retroperitoneal location)
      2. Age >= 18 years
      3. ECOG 0-2
      4. No prior history of radiation to area to be irradiated
      5. No plans for neoadjuvant chemotherapy
      6. Localized (non-metastatic) disease
      7. Visits: Enrollment, once during treatment, once after completion of radiation, every 3-6 mos after surgery
- Adjuvant High Risk
- Survivorship
  - VICCSAR2020
    Enhanced Recovery After Surgery in Extremity Soft Tissue Sarcoma
    - Key eligibility:
      1. Any patient treated with surgical excision of an extremity sarcoma